Brokerages Set Mesoblast Limited (NASDAQ:MESO) Price Target at $13.67

Shares of Mesoblast Limited (NASDAQ:MESOGet Free Report) have earned a consensus recommendation of “Hold” from the six analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $13.67.

MESO has been the subject of a number of recent research reports. StockNews.com raised shares of Mesoblast from a “sell” rating to a “hold” rating in a report on Monday, March 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Mesoblast in a report on Friday, January 12th.

Read Our Latest Report on MESO

Institutional Trading of Mesoblast

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Lazari Capital Management Inc. lifted its holdings in shares of Mesoblast by 9.3% during the 3rd quarter. Lazari Capital Management Inc. now owns 94,034 shares of the company’s stock worth $116,000 after acquiring an additional 8,000 shares during the period. Prosperity Wealth Management Inc. bought a new stake in shares of Mesoblast during the 3rd quarter worth approximately $79,000. Wells Fargo & Company MN lifted its holdings in shares of Mesoblast by 55.0% during the 2nd quarter. Wells Fargo & Company MN now owns 52,813 shares of the company’s stock worth $206,000 after acquiring an additional 18,747 shares during the period. BlackRock Inc. lifted its holdings in shares of Mesoblast by 68.6% during the 2nd quarter. BlackRock Inc. now owns 140,716 shares of the company’s stock worth $550,000 after acquiring an additional 57,252 shares during the period. Finally, EWA LLC bought a new stake in shares of Mesoblast during the 1st quarter worth approximately $40,000. Institutional investors own 2.60% of the company’s stock.

Mesoblast Stock Up 0.9 %

Shares of MESO opened at $2.31 on Monday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.95 and a current ratio of 2.71. The firm has a market cap of $234.54 million, a P/E ratio of -2.06 and a beta of 3.44. Mesoblast has a 52 week low of $1.61 and a 52 week high of $10.24. The firm’s 50-day simple moving average is $2.01 and its 200 day simple moving average is $2.27.

About Mesoblast

(Get Free Report

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

Read More

Analyst Recommendations for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.